These weaponized insulins can activate the human insulin receptor and lower blood glucose in zebrafish and mouse models of diabetes, indicating a potential future use as fast-acting drugs in the treatment of diabetes (Ahorukomeye et al., 2019 ▸). The gene discussed is INSR; the disease is diabetes mellitus.